z-logo
Premium
CD4 + CD25 + regulatory T lymphocytes in allergy and asthma
Author(s) -
Shi H.Z.,
Qin X.J.
Publication year - 2005
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2005.00844.x
Subject(s) - il 2 receptor , immunology , foxp3 , cytotoxic t cell , tumor necrosis factor alpha , immune system , cytokine , biology , medicine , t cell , in vitro , biochemistry
 Allergic asthma is characterized by airway hyper‐responsiveness and chronic mucosal inflammation mediated by CD4 + Th2 lymphocytes. Regulatory CD4 + CD25 + T cells are important components of the homeostasis of the immune system, as impaired CD4 + CD25 + T cell activity can cause autoimmune diseases and allergy. The mechanism of suppression by CD4 + CD25 + T cells remains controversial; different in vivo and in vitro studies raise possible roles for the immunosuppressive cytokines interleukin‐10 and transforming growth factor‐ β , forkhead transcription factor Foxp3, glucocorticoid‐induced tumor necrosis factor receptor, cytotoxic lymphocyte associated antigen‐4, 4‐1BB costimulator receptor, a CD4‐related molecule LAG‐3, and neuropilin‐1. Current data suggest that Th2 responses to allergens are normally suppressed by CD4 + CD25 + T cells. Suppression by CD4 + CD25 + T cells is decreased in allergic individuals. Furthermore, CD4 + CD25 + T cells play a key role in regulating airway eosinophilic inflammation. The immunomodulatory properties of CD4 + CD25 + T cells do extend to Th2 responses, most notably by limiting the development of a proinflammatory CD4 + Th2 phenotype characterized by reduced cytokine production. An understanding of the roles of CD4 + CD25 + T cells in vivo could provide better insight into the design of novel approaches to modulate the chronic airway inflammatory reaction evident in bronchial asthma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here